Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies

Liu, Q., Garner, Paul ORCID: https://orcid.org/0000-0002-0607-6941, Wang, Y., Huang, B. H. and Smith, Helen ORCID: https://orcid.org/0000-0002-6252-3793 (2008) 'Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies'. BMC Public Health, Vol 8, :365.

Preview

Text Garner_drugs_and_herbs_given_to_prevent_hepatotoxicity_of_tb_therapy.pdf - Published Version Available under License Creative Commons Attribution No Derivatives. Download (230kB)

Abstract

Background: Drugs to protect the liver are frequently prescribed in some countries as part of treatment for tuberculosis. The biological rationale is not clear, they are expensive and may do harm. We conducted a systematic review to a) describe the ingredients of "liver protection drugs"; and b) compare the evidence base for the policy against international standards.

Methods: We searched international medical databases (MEDLINE, EMBASE, LILACS, CINAHL, Cochrane Central Register of Controlled Trials, and the specialised register of the Cochrane Infectious Diseases Group) and Chinese language databases (CNKI, VIP and WanFang) to April 2007. Our inclusion criteria were research papers that reported evaluating any liver protection drug or drugs for preventing liver damage in people taking anti-tuberculosis treatment. Two authors independently categorised and extracted data, and appraised the stated methods of evaluating their effectiveness.

Results: Eighty five research articles met our inclusion criteria, carried out in China (77), India (2), Russia (4), Ukraine (2). These articles evaluated 30 distinct types of liver protection compounds categorised as herbal preparations, manufactured herbal products, combinations of vitamins and other non-herbal substances and manufactured pharmaceutical preparations. Critical appraisal of these articles showed that all were small, poorly conducted studies, measuring intermediate outcomes. Four trials that were described as randomised controlled trials were small, had short follow up, and did not meet international standards.

Conclusion: There is no reliable evidence to support prescription of drugs or herbs to prevent liver damage in people on tuberculosis treatment.

Item Type:	Article
Uncontrolled Keywords:	china, tuberculosis,drugs, herbs, liver damage
Subjects:	WF Respiratory System > Tuberculosis > WF 360 Drug therapy QV Pharmacology > Drug Standardization. Pharmacognosy. Medicinal Plants > QV 766 Medicinal plants (General) WI Digestive System > WI 140 Diseases (General) ?? wb_55_c4 ??
Faculty: Department:	Groups (2002 - 2012) > International Health Group
Digital Object Identifer (DOI):	https://doi.org/10.1186/1471-2458-8-365
Depositing User:	Philomena Hinds
Date Deposited:	15 Jun 2010 11:08
Last Modified:	06 Sep 2019 10:14
URI:	https://archive.lstmed.ac.uk/id/eprint/843

Statistics

View details

Actions (login required)

Edit Item